Related Experiment Video

Updated: Jul 4, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer

Raphael A Nemenoff1, Mary Weiser-Evans, Robert A Winn

  • 1Division of Renal Diseases, Department of Medicine, School of Medicine, University of Colorado Denver, Denver, CO 80262, USA.

PPAR Research
|May 30, 2008
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARgamma) activation shows promise for treating and preventing lung cancer. Research indicates it inhibits cancer cell growth, invasiveness, and metastasis, offering a potential chemopreventive strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality with poor survival rates.
  • There is an urgent need for novel therapeutic and preventive strategies.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is implicated in cancer development.

Purpose of the Study:

  • To review the biological and mechanistic roles of PPARgamma in lung cancer.
  • To focus on the implications of PPARgamma activation in nonsmall cell lung cancer (NSCLC).
  • To evaluate PPARgamma as a therapeutic and chemopreventive target.

Main Methods:

  • Review of preclinical studies examining thiazolidinediones (e.g., rosiglitazone, pioglitazone) on lung cancer cells.
  • Analysis of in vitro and in vivo xenograft models.
  • Examination of emerging data on PPARgamma activation via Wnt signaling and prostaglandin pathways.

Main Results:

  • Activation of PPARgamma inhibits cancer cell proliferation, invasiveness, and metastasis.
  • PPARgamma can be activated by direct ligand binding or indirectly through other signaling pathways.
  • Preclinical and retrospective clinical data suggest PPARgamma activation as a viable chemopreventive approach.

Conclusions:

  • PPARgamma activation is a promising target for lung cancer treatment and prevention.
  • Further research into PPARgamma's role, particularly in NSCLC, is warranted.
  • PPARgamma modulation offers potential for novel chemopreventive strategies against lung cancer.

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Signal Transduction: Overview01:26

Signal Transduction: Overview

Cells respond to many types of information, often through receptor proteins positioned on the membrane. They respond to chemical signals, such as hormones, neurotransmitters, and other signaling molecules, initiating a series of molecular reactions to produce an appropriate response. This is called signal transduction. Cells also coordinate different responses elicited by the same signaling molecule via mediators, allowing molecular cross-talk.
Typically, signal transduction involves three...
Peroxisomes01:24

Peroxisomes

Peroxisomes are specialized organelles present in fungi, plant, and animal cells. It can vary in number, size, morphology, and activity depending on the type of tissue and the nutritional state of the cell. For example, cells with active lipid metabolism, such as adipocytes, neurons, and hepatocytes, have more peroxisomes than other cells in the body. Besides their primary role in breaking down complex organic molecules, peroxisomes can also synthesize specific macromolecules and participate in...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...